Quality of life study in patients with unresectable locally advanced or metastatic pancreatic cancer treated with gemcitabine in combination with nab-paclitaxel versus gemcitabine alone:ax-panc-sy001: A phase II randomized study.

被引：2
|
作者：
Yalcin, Suayib
Dane, Faysal
Oksuzoglu, Berna
Yildirim, Nuriye
Isikdogan, Abdurrahman
Ozkan, Metin
Demirag, Guzin
Coskun, Hasan Senol
Karabulut, Bulent
Evrensel, Turkkan
Ustaoglu, Mehmet Ali
Ozdemir, Feyyaz
Turna, Hande
Yavuzsen, Tugba
Aykan, Faruk
Sevinc, Alper
Akbulut, Hakan
Yuce, Deniz
Hayran, Mutlu
Kilickap, Saadettin
机构：
[1] Hacettepe Univ, Ankara, Turkey
[2] Marmara Univ, Istanbul, Turkey
[3] Dr A Y Ankara Oncol Training & Res Hosp, Ankara, Turkey
[4] Ankara Numune Training & Res Hosp, Ankara, Turkey
[5] Dicle Univ, Med Sch, Diyarbakir, Turkey
[6] Erciyes Univ, Kayseri, Turkey
[7] Ondokuzmayis Univ Med Oncol, Samsun, Turkey
[8] Akdeniz Univ, Antalya, Turkey
[9] Ege Univ, Izmir, Turkey
[10] Uludag Univ, Pittsburgh, PA USA
[11] Lutfi Kirdar Hosp, Istanbul, Turkey
[12] Karadeniz Tech Univ, Fac Med, Trabzon, Turkey
[13] Istanbul Univ, Cerrahpasa Sch Med, Istanbul, Turkey
[14] Dokuz Eylul Univ, Oncol Inst, Izmir, Turkey
[15] Istanbul Univ, Inst Oncol, Istanbul, Turkey
[16] Gaziantep Univ, Gaziantep, Turkey
[17] Hacettepe Univ, Canc Inst, Ankara, Turkey
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 04期
关键词：
D O I：
10.1200/JCO.2018.36.4_suppl.346
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
346
引用
收藏
页数：1
相关论文
共 50 条
  • [21] The Phase 1 Study of Concurrent Chemoradiation Therapy With Gemcitabine and Nab-Paclitaxel for Unresectable Locally Advanced Pancreatic Adenocarcinoma Patients
    Ioka, T.
    Katayama, K.
    Takada, R.
    Fukutake, N.
    Ohkawa, K.
    Akita, H.
    Takahashi, H.
    Konishi, K.
    Teshima, T.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02): : S205 - S205
  • [22] Phase I Study of Chemoradiation Therapy (nab-Paclitaxel/Gemcitabine) in 18 Patients with Unresectable Locally Advanced Pancreatic Adenocarcinoma
    Ioka, Tatsuya
    Katayama, Kazuhiro
    Hibino, Kenji
    Yutaro, Abe
    Tamura, Takeshi
    Takada, Ryoji
    Fukutake, Nobuyasu
    Ashida, Reiko
    Ohkawa, Kazuyoshi
    Akita, Hiroshi
    Takahashi, Hidenori
    Hirata, Takero
    Teshima, Teruki
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2015, 30 : 147 - 147
  • [23] Randomized phase III study of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (MPACT)
    Von Hoff, Daniel D.
    Ervin, Thomas J.
    Arena, Francis P.
    Chiorean, E. Gabriela
    Infante, Jeffrey R.
    Moore, Malcolm J.
    Seay, Thomas E.
    Tjulandin, Sergei
    Ma, Wen Wee
    Saleh, Mansoor N.
    Harris, Marion
    Reni, Michele
    Ramanathan, Ramesh K.
    Tabernero, Josep
    Hidalgo, Manuel
    Van Cutsem, Eric
    Goldstein, David
    Wei, Xinyu
    Iglesias, Jose Luis
    Renschler, Markus Frederic
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [24] A Phase II study of weekly nab-paclitaxel in combination with gemcitabine in patients with metastatic breast cancer.
    Zhao, Yannan
    Lv, Fangfang
    Chen, Shen
    Lu, Yunhua
    Cao, Enying
    Wang, Zhonghua
    Zhang, Jian
    Zhang, Sheng
    Cao, Jun
    Zheng, Chunlei
    Wang, Leiping
    Wang, Biyun
    Hu, Xichun
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [25] Phase II LAPACT Trial of Nab-Paclitaxel Plus Gemcitabine for Patients With Locally Advanced Pancreatic Cancer
    Bekaii-Saab, Tanios
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (03) : 9 - 10
  • [26] Phase Ib study of gemcitabine, nab-paclitaxel, and ficlatuzumab in patients with advanced pancreatic cancer
    Perez, Kimberly
    Weekes, Colin D.
    Cleary, James M.
    Abrams, Thomas Adam
    Blaszkowsky, Lawrence Scott
    Enzinger, Peter C.
    Giannakis, Marios
    Goyal, Lipika
    Meyerhardt, Jeffrey A.
    Rubinson, Douglas Adam
    Yurgelun, Matthew B.
    Stonely, Danielle
    Raghavan, Srivatsan
    Bakir, Basil
    Das, Koushik
    Pitarresi, Jason
    Aguirre, Andrew
    Needle, Michael N.
    Rustgi, Anil
    Wolpin, Brian M.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [27] A multicenter randomized phase II study of NPC-1C (N) in combination with gemcitabine (G) and nab-paclitaxel (A) versus G and A alone in patients with metastatic or locally advanced pancreatic cancer (PC) previously treated with folfirinox (F)
    Duffy, Austin G.
    Beg, Muhammad Shaalan
    Greten, Tim F.
    Beatson, Melony A.
    Mavroukakis, Sharon
    Patel, Sandip Pravin
    Morse, Michael A.
    Arlen, Philip M.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [28] Cost-Effectiveness of Nab-Paclitaxel and Gemcitabine Versus Gemcitabine Monotherapy for Patients with Unresectable Metastatic Pancreatic Cancer in Japan
    Morimoto, Kosuke
    Moriwaki, Kensuke
    Kaneyasu, Takako
    Nakayama, Hitomi
    Shimozuma, Kojiro
    VALUE IN HEALTH REGIONAL ISSUES, 2022, 28 : 54 - 60
  • [29] E4201: Randomized phase II study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with locally advanced, unresectable, pancreatic cancer (LAPC): Quality-of-life (QOL) analysis
    Cardenes, H. R.
    Powell, M.
    Loehrer, P. J.
    Wagner, L. I.
    Cella, D. F.
    Brell, J.
    Ramanathan, R. K.
    Crane, C. H.
    Alberts, S. R.
    Benson, A. B.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [30] Gemcitabine with nab-paclitaxel in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC): A quality of life randomized cross-over study (QOLINPAC)
    Chiritescu, G.
    Dumon, K.
    Verslype, C.
    Prenen, H.
    Houbiers, G.
    Peeters, M.
    Janssens, J.
    Van Daele, D.
    Laurent, S.
    Arts, J.
    Hendrickx, K.
    Borbath, I.
    Ferrante, M.
    Bastin, F.
    Goeminne, J.
    Van Laethem, J.
    Vanderstraeten, E.
    Decaestecker, J.
    Van Vaerenbergh, W.
    Delhougne, B.
    Van Cutsem, E.
    ANNALS OF ONCOLOGY, 2018, 29 : 101 - 101
12345